Expression of CXCR4 in Patients With Systemic Lupus Erythematosus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-31

Study Completion Date

2022-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to estimate the possible role of CD184 in the pathogenesis of SLE; comparing its level among SLE cases to healthy controls.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus

NCT00008749

Lupus Erythematosus, Systemic

UNKNOWN

IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage

NCT05045417

Systemic Lupus Erythematosus

UNKNOWN

Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)

NCT00094380

Lupus Erythematosus, Systemic Lupus Nephritis

COMPLETED PHASE1/PHASE2

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants

NCT05984251

Vasculitis Systemic Lupus Erythematosus (SLE)

COMPLETED PHASE1

Interdisciplinary Study Group of Lupus Erythematosus (ISGLE)

NCT00420173

Cutaneous Lupus Erythematosus

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Detection of CXCR4 (CD184) expression on CD19+ B cells by flow cytometry in patients of SLE, comparing its level in the development of lupus activity and pathogenic process of SLE internal organ involvement/ mucocutaneus and/or musculoskeletal involvement. Identify this correlation will be useful for clarifying other accessory factors to improve the diagnosis, better treatment strategy, follow up as well as prognosis for these patients

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Lupus Erythematosus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SLE cases in remission

according to SLE Disease Activity Index (SLEDAI) inactive disease will be considered as SLEDAI \<5

No interventions assigned to this group

SLE cases in activity

according to SLE Disease Activity Index (SLEDAI) Active disease will be defined as SLEDAI ≥ 5

No interventions assigned to this group

Control group

Healthy age and sex matched subjects.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed SLE patients diagnosed and fulfilled the SLE classification criteria according to the 2019 ACR/EULAR classification criteria for SLE (Aringer et al., 2019)
* Willing and agreed to be included in the study.

Exclusion Criteria

* Childhood SLE.
* SLE-patients will refuse to consent to this study.
* Other autoimmune diseases.
* Known or suspected malignancies, especially B cell lymphoma.

Minimum Eligible Age

16 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes